{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-288264","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.153938+00:00","generated_at":"2026-05-16T18:34:19.765197+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics raises ~$4M in registered direct offering paid in gold coins; redeems $3.4M note","bullets":["Priced 3,540,000 shares and 8,570,203 pre-funded warrants at $0.3303/unit, gross proceeds ~$4M.","Payment in sovereign-issued .9999 fine gold coins valued at $4,069.18/oz, intent to liquidate to USD.","Concurrent private placement of 12,110,203 warrants at $0.3303, exercisable after stockholder approval.","Redeemed final Promissory Note (third tranche) of $3.4M principal plus 6% premium for total $3.604M.","Net proceeds for general corporate purposes, including debt satisfaction; offering closes Nov. 19, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-288264","json":"https://secwatch.observer/filing/0001193125-25-288264.json","markdown":"https://secwatch.observer/filing/0001193125-25-288264.md","text":"https://secwatch.observer/filing/0001193125-25-288264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525288264/0001193125-25-288264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525288264/fblg-20251118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:34:19.765197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72bd4fbce8fec46dc55be7caad11973bad36e5ef","claim":"FibroBiologics, Inc. issued 8,570,203 pre-funded warrants of warrant to a single investor for sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement.","evidence_excerpt":"below. The exercise price of the Warrants is $0.3303 per share. The purchase price for the Shares or Pre-Funded Warrants will be paid not in cash but with sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement, delivered to the Company’s depository. The Company","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525288264/0001193125-25-288264-index.htm","confidence":0.99,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"8,570,203 pre-funded warrants"},{"label":"Purchaser","value":"a single investor"},{"label":"Consideration","value":"sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement"}],"fact_type":"equity_issuance"},{"claim_id":"b8e7714b00bf026c1fbd8a3e67c9349c4f074073","claim":"FibroBiologics, Inc. issued 3,540,000 shares of common stock to a single investor for sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement.","evidence_excerpt":"below. The exercise price of the Warrants is $0.3303 per share. The purchase price for the Shares or Pre-Funded Warrants will be paid not in cash but with sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement, delivered to the Company’s depository. The Company","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525288264/0001193125-25-288264-index.htm","confidence":0.99,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"3,540,000 shares"},{"label":"Purchaser","value":"a single investor"},{"label":"Consideration","value":"sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement"}],"fact_type":"equity_issuance"},{"claim_id":"e4509afd7187cc29357211cab295a3ed227bd84a","claim":"FibroBiologics, Inc. issued 12,110,203 shares of warrant to the Purchaser for Not stated separately; warrants issued in connection with the Registered Direct Offering.","evidence_excerpt":"Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchaser, in a concurrent private placement, warrants to purchase one share of its common stock for each share of common stock or Pre-Funded Warrant purchased in the Registered Direct Offering, for an aggregate of 12,110,203 shares of Common Stock (the “Warrants”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525288264/0001193125-25-288264-index.htm","confidence":0.99,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"12,110,203 shares"},{"label":"Purchaser","value":"the Purchaser"},{"label":"Consideration","value":"Not stated separately; warrants issued in connection with the Registered Direct Offering"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}